Semax
Also Known As: Semax peptide, ACTH 4-7 PGP, Met-Glu-His-Phe-Pro-Gly-Pro, Semax nasal spray, ACTH analog nootropic, Heptapeptide nootropic, Russian nootropic peptide, Pro-Gly-Pro analog ACTH, Semax cognitive peptide, Semax neuroprotective, N-acetylated Semax, Semax 0.1% nasal, Semax 1% nasal, nootropic, ACTH analog, brain peptide
Semax is a research-grade Synthetic heptapeptide analog of ACTH 4-7 with Pro-Gly-Pro extension targeting Melanocortin receptors studied in Immunity & Wellness research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
A nootropic/neuroprotective peptide used in Russia for stroke and cognition.
At A Glance
| Category | Immunity & Wellness |
|---|---|
| Compound Class | Synthetic heptapeptide analog of ACTH 4-7 with Pro-Gly-Pro extension; neuroprotective and nootropic |
| Molecular Target | Melanocortin receptors (MC2R/MC4R); BDNF/NGF upregulation; serotonin/dopamine axis; enkephalinase inhibition |
| Molecular Weight | 813.9 Da |
| Amino Acid Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| CAS Number | 80714-61-0 |
| Half-Life | ~5 minutes |
| WADA Status | not_listed |
| Evidence Tier | Research Compound |
Mechanism Of Action
It stimulates the rapid release of Brain-Derived Neurotrophic Factor (BDNF), which encourages neurons to form new connections, dramatically improving learning capacity and mental stamina.
Studied For
- Ischemic stroke recovery
- Cognition / memory enhancement
- Optic nerve disorders
- CNS disorders research
- ADHD research
- BDNF upregulation
- Neuroprotection
- Anxiety reduction
- Depression models
- Transient ischemic attack (TIA) models
- Serotonin upregulation
- Dopamine enhancement
- Focus and attention research
- Immune modulation
- Melanocortin system cognitive effects
- Neurogenesis research
- Post-stroke cognitive improvement
- brain fog
- cognitive enhancement
- ADHD
- stroke recovery
- neuroprotection
- memory improvement
- BDNF increase
- focus
Reported Research Findings
Russian use and studies report benefit in stroke and cognition. Animal data show neuroprotection and improved learning. Predominantly Russian-literature and preliminary.
Safety And Handling Notes
Reported well tolerated; intranasal local irritation; limited independent adverse-event data.
Thin, geographically concentrated evidence; registered in Russia but not FDA or EMA approved. Research use only elsewhere.
Regulatory Status
Registered in Russia; not FDA or EMA approved.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.